Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer Aug 2, 2022
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study Jul 7, 2022
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event Jun 2, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference May 18, 2022
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities Apr 27, 2022
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update Mar 23, 2022
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 12, 2021
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 8, 2021
